1. Generics Bulletin

BGMA Suggests Tweaks To UK Statutory Pricing Scheme Proposals

Generics And Biosimilars Body Continues To Welcome Recognition Of Competition Impact

 
• By Dave Wallace

UK generics and biosimilars industry association the BGMA has published a formal response to a government consultation on the statutory scheme for branded medicine pricing, welcoming the recognition of the impact of competition in the government’s proposals but suggesting amendments to “minimize unintended consequences and align it to how the market operates.”

Two UK pound coins surrounded by tablets and capsules, medicines pricing cost concept
The BGMA has published its response to UK government proposals on the statutory scheme for branded medicine pricing • Source: Shutterstock

Amendments have been suggested by the British Generic Manufacturers Association to UK government proposals to overhaul the country’s statutory scheme for branded medicine pricing.

The statutory scheme is separate from, but complementary to, the Voluntary Scheme for Branded Medicines Pricing and Access that has been the subject of legal wrangling since the BGMA was excluded from participating directly in current VPAS renegotiations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.